Trial Profile

An Open-label, Multi-center Phase Ib/II Study of MK-1045 (CN201) in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 07 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CN 201 (Primary)
Indications Precursor B-cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions; Therapeutic Use
Sponsors Curon Biopharmaceutical; MSD China

Most Recent Events

27 Apr 2025 Planned End Date changed from 31 Jul 2025 to 31 Jan 2027.
27 Apr 2025 Planned primary completion date changed from 31 May 2025 to 31 Jan 2027.
04 Jun 2024 Preliminary results assessing safety and efficacy of CN201 were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com